Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/
WHO declaration of swine flu pandemic under scrutiny (IP Watch) (IP Watch) (IP Watch) (Spicy IP) (IP Watch)
GSK ‘Open Innovation Agenda’ – will make 13,500 compounds related to deadliest strain of malaria freely available to researchers, the public (IP Watch) (Ills, Pills And Attendant Thrills)
When Proprietary Harry meets Generic Sally (IP finance)
Biodiversity ‘EcoChic’ at UN: ‘Organic, fair trade, and damn sexy’ (IP Watch)
GSK ‘Open Innovation Agenda’ – will make 13,500 compounds related to deadliest strain of malaria freely available to researchers, the public (IP Watch) (Ills, Pills And Attendant Thrills)
WHO declaration of swine flu pandemic under scrutiny (IP Watch) (IP Watch) (IP Watch) (Spicy IP) (IP Watch)
Africa: WHO’s strategy good news for Africa but what about IP? – ‘indirect consumer tax’ to fund UN public health initiatives (Afro-IP)
Canada: Submissions on Canada-EU trade deal: Canadian Generic Pharma Assoc. wants IP out (Michael Geist)
Canada: Intellectual property and agriculture – CDC Triffid seed story (ipblog.ca)
EU: Records of the 1st, 2nd and 3rd expert meetings on SPCs (The SPC Blog)
EU: Cooperation between Board of Appeal and National Court / acceleration of appeal proceedings: Human Genome Sciences v Eli Lilly (EPLAW)
Indian pharma starts 2010 with infringement lawsuits in the United States: Teva Women’s Health, Inc. v. Lupin Ltd. concerning LoSeasonique and Takeda Pharmaceutical Company Limited et al v. Aurobindo Pharma Limited (Patentcircle)
India/US: Indian pharma sector ‘fares well’ in US disputes (PatLit)
India: The woes of the grassroot innovator in the agricultural sector (Spicy IP)
South Africa: Biopiracy in Alice – Schwabe Pharamaceuticals wishes to patent method for extracting active ingredient in cough medicine from pelargonium roots (Afro-IP)
UK: Okay to split costs where actions are joined, says Court of Appeal: Actavis UK Ltd v Eli Lilly & Co Ltd (PatLit)
USPTO asks out of gene patenting case (again): Association for Molecular Pathology et al v USPTO et al (Patent Docs)
US: Obstacles to correcting patent terms adjustments (IP Frontline)
USPTO and DOJ will not seek review: Wyeth v. Kappos (Patent Docs)
US: Calculating PTA: PTO to offer ‘guidance for expediting requests’ (Patently-O)
US: Senate votes against Bill allowing Americans to import prescription drugs (Pharmacapsules@Gowlings)
US: Governors write President in support of 12-year data exclusivity period (Patent Docs)
US: Obama moving to renegotiate biologics exclusivity period (Pharmacapsules@Gowlings)
US: Law Professors Adelman and Holman contend that data exclusivity is secondary issue in follow-on biologics debate (Patent Docs)
US: Monsanto wins partial summary judgment; licenses to Pioneer did not allow Pioneer to ‘stack’ Optimum GAT on Monsanto’s Roundup Ready product (BlawgIT)
US: Study examines Paragraph IV settlement and litigation success rates (Patent Docs)
US: CAFC: Terminal disclaimer not valid when underlying patent expired: Boehringer Ingelheim Int’l v Barr Laboratories, Inc (Peter Zura’s 271 Patent Blog)
Aerius (Desloratadine) – Canada: Federal Court finds Pharmascience’s allegations of non-infringement, anticipation, obviousness and overbreadth of one patent and non-infringement of second patent justified; application under the NOC Regulations dismissed: Schering v Pharmascience (Pharmacapsules@Gowlings)
Angiomax (Bivalirudin) – US: PTO denies the Medicines Company’s request for reconsideration for patent term extension (FDA Law Blog)
Botox (Botulinum toxin) – Owner of Bellevue Beauty Salon found guilty of injecting fake Botox (Seattle Trademark Lawyer)
Gardasil (HPV vaccine) – UK: IPO: Georgetown University’s Gardasil SPC application rejected because marketing authorisation comprised further active ingredient in addition to that listed in product definition in SPC application (SPC blog)
Gardasil and Silgard (HPV vaccine) – Portugal: Tribunal do Commercio de Lisboa: Cancellation of Portuguese SPC 260 for Gardasil and Silgard, referring to Merck & Co’s patent EP0817851 (The SPC Blog)
Temodar (Temozolmide) – US: District Court rules against Merck in patent infringement suit against Teva (SmartBrief)
Xalacom (Latanoprost) – Canada: Federal Court grants prohibition to Pfizer, finding Pharamscience allegations for invalidity not justified: Pfizer v Pharmascience (Pharmacapsules@Gowlings)
Zyvox (Linezolid) – US: Pfizer sues Teva for infringing Zyvox patent (The IP Factor)